pipetcpt
: open source softwarespipetpro
: private repositories
pipetpro
only
2019-04-08
THe members of PIPET (Alphabetical orders)
crckhm
김혜민 CKdlaqudgml2
임병희 PBeheh9191
박은희 AAoceanofscience
임동석 FYparkseeh
박시현 PPpipetpro
PIPET ProQJeon
전상일 QJSeunghoon-Han
한승훈 FHshanmdphd
한성필 FPSojinee
이소진 GLSOOYOUNG-KANG
강수영 QSSueinchoi
최수인 RS
서울성모병원 임상약리과 - 가톨릭대학교 계량약리학연구소 (PIPET)
- 모르는 것을 끝까지 파고드는 호기심이 명문대 졸업장을 이긴다. (졸업장, 면허증 하나로 편히 살려는 사람 사절)
- 학문에 있어서는 계급장 떼고 토론하라. (上命下服과 science는 함께할 수 없다.)
- 모르는 것은 모른다고 말하라. (모름을 숨기면 배울 기회를 차버리는 것이다.)
- 배우고 난 후 생각하고 질문하지 않는다면 배운 것이 아니다. (남이 지식을 전달해 줄 수 있어도 생각까지 대신해 줄 수는 없다.)
- 사람의 품성은 아랫사람을 대하는 태도에서 거짓없이 드러난다. (위만 쳐다보지 말고 주변이 함께 일하고 싶은 사람이 되기를)
- 속도보다 방향이다.
- 윗사람에게 무조건 순종하거나 비위 맞추는 사람을 교수로 들이지 말라. (아래에도 같은 것을 요구하여 대학을 망친다.)
- 각광받지 못하는 주제라도 깊이 파고들 수 있는 기개를 지녀라.
- 배우는 사람의 잠재력을 최대한 끌어내는 것이 수련이다. (일을 시키는 것은 수련의 방법이지 목적이 아니다.)
- 이 메모를 존중하는 것도, 휴지조각으로 만드는 것도 교수들에게 달려있다. (지키기 싫은 교수는 떠나라.)
2018.12
임동석 (Director, PIPET)
- CRM_simulation: Early clinical trial designing using CRM
- Intravenous_HBIG: 정맥 주사용 B형 간염 항체 용법용량 별 목표 농도 도달률 예측
- AntihypertensiveDrugs: Anti-Hypertensive Drugs 계산 프로그램
- TMDD_GC1118: TMDD_PK/Receptor Occupancy- GC1118
- PKsimIV: PK simulator IV Ver.
- PKsimEV: PK Simulator Extravascular Ver.
[1] S. H. Bae, D. Yim, H. Lee, et al. “Application of Pharmacometrics in Pharmacotherapy: Open-Source Software for Vancomycin Therapeutic Drug Management”. In: Pharmaceutics 11.5 (May. 2019), p. 224. DOI: 10.3390/pharmaceutics11050224. <URL: https://doi.org/10.3390/pharmaceutics11050224>.
[2] S. Cho, S. Han, J. Ghim, et al. “A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males”. In: BioDrugs 33.2 (Mar. 2019), pp. 173-181. DOI: 10.1007/s40259-019-00340-x. <URL: https://doi.org/10.1007/s40259-019-00340-x>.
[3] S. Choi, S. Han, S. Jeon, et al. “Quantitative Prediction of Human Pharmacokinetics and Pharmacodynamics of CKD519, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP)”. In: Pharmaceutics 11.7 (Jul. 2019), p. 336. DOI: 10.3390/pharmaceutics11070336. <URL: https://doi.org/10.3390/pharmaceutics11070336>.
[4] S. Han, S. Han, K. Kim, et al. “Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs”. In: Frontiers in Pharmacology 10 (Nov. 2019). DOI: 10.3389/fphar.2019.01419. <URL: https://doi.org/10.3389/fphar.2019.01419>.
[5] T. M. Polasek, A. Rostami-Hodjegan, D. Yim, et al. “What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing”. In: The AAPS Journal 21.2 (Jan. 2019). DOI: 10.1208/s12248-018-0286-6. <URL: https://doi.org/10.1208/s12248-018-0286-6>.
[6] S. H. Bae, W. Park, S. Han, et al. “Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans”. In: The Korean Journal of Physiology & Pharmacology 22.3 (2018), p. 321. DOI: 10.4196/kjpp.2018.22.3.321. <URL: https://doi.org/10.4196/kjpp.2018.22.3.321>.
[7] S. Choi, S. Jeon, and S. Han. “Population pharmacokinetic analysis of metformin administered as fixed-dose combination in Korean healthy adults”. In: Translational and Clinical Pharmacology 26.1 (2018), p. 25. DOI: 10.12793/tcp.2018.26.1.25. <URL: https://doi.org/10.12793/tcp.2018.26.1.25>.
[8] S. Han, B. Lim, H. Lee, et al. “Development of a user-friendly training software for pharmacokinetic concepts and models”. In: Translational and Clinical Pharmacology 26.4 (2018), p. 166. DOI: 10.12793/tcp.2018.26.4.166. <URL: https://doi.org/10.12793/tcp.2018.26.4.166>.
[9] D. Yim. “Five years of the CiPA project (20132018): what did we learn?” In: Translational and Clinical Pharmacology 26.4 (2018), p. 145. DOI: 10.12793/tcp.2018.26.4.145. <URL: https://doi.org/10.12793/tcp.2018.26.4.145>.
[10] S. Han, G. H. Na, and D. Kim. “A 6-month mixed-effect pharmacokinetic model for post-transplant intravenous anti-hepatitis B immunoglobulin prophylaxis”. In: Drug Design, Development and Therapy Volume 11 (Jul. 2017), pp. 2099-2107. DOI: 10.2147/dddt.s134711. <URL: https://doi.org/10.2147/dddt.s134711>.
[11] W. Huh, H. Oh, J. S. Han, et al. “Hydrochlorothiazide does not increase furosemide's effects in end-stage renal disease”. In: Translational and Clinical Pharmacology 25.1 (2017), p. 28. DOI: 10.12793/tcp.2017.25.1.28. <URL: https://doi.org/10.12793/tcp.2017.25.1.28>.
[12] D. Jang, S. Han, and D. Yim. “Development of an automated appendix generation system (ARGUS) for clinical study reports”. In: Translational and Clinical Pharmacology 25.1 (2017), p. 34. DOI: 10.12793/tcp.2017.25.1.34. <URL: https://doi.org/10.12793/tcp.2017.25.1.34>.
[13] G. Park, S. H. Bae, W. Park, et al. “Drug&ndash$\mathsemicolon$drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer”. In: Drug Design, Development and Therapy Volume11 (Mar. 2017), pp. 1043-1053. DOI: 10.2147/dddt.s131797. <URL: https://doi.org/10.2147/dddt.s131797>.
[14] W. Park, G. Park, S. Han, et al. “Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients”. In: Cancer Chemotherapy and Pharmacology 80.2 (Jun. 2017), pp. 363-369. DOI: 10.1007/s00280-017-3373-y. <URL: https://doi.org/10.1007/s00280-017-3373-y>.
[15] N. Rajasekaran, H. S. Jung, S. H. Bae, et al. “Effect of HPV E6/E7 siRNA with Chemotherapeutic Agents on the Regulation of TP53/E2F Dynamic Behavior for Cell Fate Decisions”. In: Neoplasia 19.10 (Oct. 2017), pp. 735-749. DOI: 10.1016/j.neo.2017.07.005. <URL: https://doi.org/10.1016/j.neo.2017.07.005>.
[16] D. Yim. “Tutorial for beginners: the concept of clearance explained using the example of a vacuum cleaner”. In: Translational and Clinical Pharmacology 25.1 (2017), p. 1. DOI: 10.12793/tcp.2017.25.1.1. <URL: https://doi.org/10.12793/tcp.2017.25.1.1>.